Trials / Completed
CompletedNCT00301223
A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain
An 8-Week Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150mg-600mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Symptoms Of Neuropathic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 309 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy, safety and tolerability for pregabalin using a flexible, optimized dose schedule compared to placebo in relieving the symptoms of neuropathic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin |
Timeline
- Start date
- 2006-02-01
- Completion
- 2007-09-01
- First posted
- 2006-03-10
- Last updated
- 2021-01-22
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00301223. Inclusion in this directory is not an endorsement.